Vineeta Gupta1, Ravindra Kumar Garg2, Sanjay Khattri3. 1. Senior Research Fellow, Department of Pharmacology and Therapeutics, King George's Medical University , Lucknow, Uttar Pradesh, India . 2. Professor and Head of Department, Department of Neurology, King George's Medical University , Lucknow, Uttar Pradesh, India . 3. Professor, Department of Pharmacology & Therapeutics, King George's Medical University , Lucknow, Uttar Pradesh, India .
Abstract
INTRODUCTION: Several investigations have been made to determine the level of alpha-synuclein in the peripheral blood of Parkinson's disease patients, but the results were very contradictory and inconclusive. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) was also found to be involved in Parkinson's disease, but there is a lack of studies investigating NF-κB in Parkinson's disease patients. As far as our knowledge goes, no study reported the level of NF-κB in serum of Parkinson's disease patients. In this context, present study was designed to make a baseline study in order to evaluate the levels of total alpha-synuclein and NF-κB in serum of Parkinson's disease patients. MATERIALS AND METHODS: Serum samples were collected from Parkinson's disease patients (n=97) and healthy controls (n=97). Their levels were determined by using Enzyme linked immunosorbent assay. RESULTS: The levels of total alpha-synuclein (patients=5.79±2.24 ng/ml, controls=6.20±1.61 ng/ml; p=0.14) and NF-κB (patients=1.38±0.99 ng/ml, controls=1.65±1.00 ng/ml; p=0.71) were lower in Parkinson's disease patients than controls, but the differences were not statistically significant. This difference was also failed to reach significance between males (alpha-synuclein (p)=0.70, NF-κB (p)=0.84) and females (alpha-synuclein (p)=0.06, NF-κB (p)=0.77) in both the groups as well as within the groups. The levels of total alpha-synuclein and NF-κB were also not associated with Parkinson's disease severity (alpha-synuclein (p) = 0.84, NF-κB (p) = 0.73). CONCLUSION: A non-significant difference in the levels of total alpha-synuclein and NF-κB between Parkinson's disease patients and controls suggested that these are not valuable biomarkers for Parkinson's disease, more specifically in Indian population.
INTRODUCTION: Several investigations have been made to determine the level of alpha-synuclein in the peripheral blood of Parkinson's diseasepatients, but the results were very contradictory and inconclusive. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) was also found to be involved in Parkinson's disease, but there is a lack of studies investigating NF-κB in Parkinson's diseasepatients. As far as our knowledge goes, no study reported the level of NF-κB in serum of Parkinson's diseasepatients. In this context, present study was designed to make a baseline study in order to evaluate the levels of total alpha-synuclein and NF-κB in serum of Parkinson's diseasepatients. MATERIALS AND METHODS: Serum samples were collected from Parkinson's diseasepatients (n=97) and healthy controls (n=97). Their levels were determined by using Enzyme linked immunosorbent assay. RESULTS: The levels of total alpha-synuclein (patients=5.79±2.24 ng/ml, controls=6.20±1.61 ng/ml; p=0.14) and NF-κB (patients=1.38±0.99 ng/ml, controls=1.65±1.00 ng/ml; p=0.71) were lower in Parkinson's diseasepatients than controls, but the differences were not statistically significant. This difference was also failed to reach significance between males (alpha-synuclein (p)=0.70, NF-κB (p)=0.84) and females (alpha-synuclein (p)=0.06, NF-κB (p)=0.77) in both the groups as well as within the groups. The levels of total alpha-synuclein and NF-κB were also not associated with Parkinson's disease severity (alpha-synuclein (p) = 0.84, NF-κB (p) = 0.73). CONCLUSION: A non-significant difference in the levels of total alpha-synuclein and NF-κB between Parkinson's diseasepatients and controls suggested that these are not valuable biomarkers for Parkinson's disease, more specifically in Indian population.
Authors: R Borghi; R Marchese; A Negro; L Marinelli; G Forloni; D Zaccheo; G Abbruzzese; M Tabaton Journal: Neurosci Lett Date: 2000-06-16 Impact factor: 3.046
Authors: Brit Mollenhauer; Valerie Cullen; Ilana Kahn; Bryan Krastins; Tiago F Outeiro; Imelda Pepivani; Juliana Ng; Walter Schulz-Schaeffer; Hans A Kretzschmar; Pamela J McLean; Claudia Trenkwalder; David A Sarracino; Jean-Paul Vonsattel; Joseph J Locascio; Omar M A El-Agnaf; Michael G Schlossmacher Journal: Exp Neurol Date: 2008-06-14 Impact factor: 5.330
Authors: Marie Westerlund; Andrea Carmine Belin; Anna Anvret; Anna Håkansson; Hans Nissbrandt; Charlotta Lind; Olof Sydow; Lars Olson; Dagmar Galter Journal: FASEB J Date: 2008-07-07 Impact factor: 5.191
Authors: D W Miller; S M Hague; J Clarimon; M Baptista; K Gwinn-Hardy; M R Cookson; A B Singleton Journal: Neurology Date: 2004-05-25 Impact factor: 9.910
Authors: Deborah C Mash; Nikhil Adi; Linda Duque; John Pablo; Mahendra Kumar; Frank R Ervin Journal: Drug Alcohol Depend Date: 2007-12-04 Impact factor: 4.492
Authors: Ruwani S Wijeyekoon; Deborah Kronenberg-Versteeg; Kirsten M Scott; Shaista Hayat; Wei-Li Kuan; Jonathan R Evans; David P Breen; Gemma Cummins; Joanne L Jones; Menna R Clatworthy; R Andres Floto; Roger A Barker; Caroline H Williams-Gray Journal: Brain Behav Immun Date: 2020-01-30 Impact factor: 19.227
Authors: Silvia M Albillos; Olimpio Montero; Sara Calvo; Berta Solano; José María Trejo; Esther Cubo Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2021-05-28